1. Home
  2. SPRO vs CXE Comparison

SPRO vs CXE Comparison

Compare SPRO & CXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.82

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Logo MFS High Income Municipal Trust

CXE

MFS High Income Municipal Trust

HOLD

Current Price

$3.66

Market Cap

117.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
CXE
Founded
2013
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
135.5M
117.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
CXE
Price
$2.82
$3.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
663.0K
84.3K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
4.36%
EPS Growth
111.81
N/A
EPS
N/A
0.07
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
$52.14
Revenue Growth
39.24
N/A
52 Week Low
$1.80
$3.40
52 Week High
$3.09
$3.88

Technical Indicators

Market Signals
Indicator
SPRO
CXE
Relative Strength Index (RSI) 55.64 41.61
Support Level $2.18 $3.64
Resistance Level $2.90 $3.78
Average True Range (ATR) 0.17 0.03
MACD 0.03 -0.01
Stochastic Oscillator 58.45 22.50

Price Performance

Historical Comparison
SPRO
CXE

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About CXE MFS High Income Municipal Trust

Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.

Share on Social Networks: